Aignostics, a pioneering company at the forefront of precision medicine, recently announced a remarkable funding round, successfully raising $34 million to further its mission of advancing healthcare through innovative data-driven solutions. Founded in 2018 as a spin-off from the prestigious Charité Berlin, Aignostics harnesses proprietary access to multimodal clinical datasets and marries it with cutting-edge AI technologies to deliver best-in-class insights that empower biopharma partners in drug discovery and clinical research. This new capital will be instrumental in scaling Aignostics’ operations across its locations in Berlin and New York, enabling the company to enhance its collaborations with biopharmaceutical companies and catalyze advancements in translational research and companion diagnostics (CDx) development. As the healthcare landscape pivots towards personalized treatment approaches, Aignostics is ideally positioned to play a pivotal role, striving to transform the way treatments are developed and implemented across multiple therapeutic areas. The backing from leading venture capital investors underscores the confidence in Aignostics' innovative approach and the potential impact it can have on future therapeutic solutions. With this funding, Aignostics aims to accelerate its R&D efforts, expand its data analysis capabilities, and ultimately bring about breakthroughs that could redefine patient outcomes. This advancement not only promises to enhance the precision and efficacy of medical interventions but also signifies a vital step towards realizing the full potential of precision medicine in today's rapidly evolving healthcare environment.
Aignostics Secures $34 Million in Series B Funding for Precision Medicine Advancements
Recently funded · $34.0M Series bBiotechnology
Get the full Aignostics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
